慢性肾衰竭患者载脂蛋白与心脑血管并发症的相关性  

Relationship between Apolipoprotein and Cardiocerebrovascular Complications in Patients with CRF

作　　者：许焱[1] 黄雯[1] 

机构地区：[1]首都医科大学附属北京同仁医院肾内科,100730

出　　处：《中国误诊学杂志》2009年第11期2524-2526,共3页Chinese Journal of Misdiagnostics

摘　　要：目的:观察维持性血液透析(MHD)对载脂蛋白(Apo)及其比值的影响,探讨慢性肾衰竭(CRF)Apo与心脑血管并发症的相关性。方法:CRF肾衰竭期或终末期患者65名,分为CRF组及MHD组,每组以是否合并心脑血管并发症再分为并发症亚组及无并发症亚组,对照组21例,观察各组ApoB、ApoA1、ApoB/ApoA1,血浆白蛋白(Alb)水平。结果:与对照组相比,CRF组ApoB、ApoB/ApoA1升高(P<0.05),而MHD组上述指标得到改善;两并发症亚组的ApoB及ApoB/ApoA1均值较相对应的无并发症亚组升高,但无统计学意义。结论:MHD可以降低ApoB及ApoB/ApoA1,但其对CRF患者心脑血管并发症的预测意义尚不确定。Objective：To assess the effect of hemodialysis on apolipoprotein AI （apoAI）, apoB and apoB/apoAI ratio and to study the relationship between apolipoprotein and cardiocerebrovascular complications in patients with chronic renal failure（CRF）. Methods：Sixty-five patients with end stage renal failure were divided into CRF group and maintain hemodialysis （MHD） group, which also including two subgroups separately： with or without cardiocerebrovascular complications. Twenty-one healthy persons were included in control group, apoAI, apoB, apoB/apoAI and serum albumin （Alb） were measured. Resultes ：Comparing with control group, apoB,apoB/apoAI level were increased in CRF group（P〈0.05）, but there was no difference between control and MHD group;In both CRF and MHD group, comparing with subgroup without cardiocerebrovascular complications, the level of apoB, apoB/apoAI ratio were higher in subgroup with complications, but there was no statistical significance. Conclusion ：Hemodialysis can decrease the level, of apoB, apoB/apoAI ratio in CRF patients, but it has to carry out more studies to discuss whether they can be the lipoprotein related risk marker of cardiocerebrovascular diseases in patients with CRF.

关 键 词：肾功能衰竭 慢性/代谢 载脂蛋白类/代谢 心血管疾病/代谢 脑血管意外/代谢 肾透析 人类 

分 类 号：R692.5[医药卫生—泌尿科学]